Prevents acute organ rejection. Sold as Simulect. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Basiliximab (sold as Simulect), first approved May 12, 1998, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Simulect | Part B | $2.0M | +11% | 202 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's DiseaseParkinson Disease (PD) · Royan Institute | Phase 1 | Recruiting | May 7, 2026 |
| Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AMLAcute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — | Not yet recruiting | May 7, 2026 |
| Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationSteroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | May 7, 2026 |
| Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant RecipientsCytomegalovirus Infections · University of Guadalajara | Phase 4 | Active, not recruiting | Feb 24, 2026 |
| Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALLAcute Lymphoblastic Leukemia, Adult · Shanxi Bethune Hospital | Phase 2 / Phase 3 | Recruiting | Jul 10, 2025 |
| Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic DiseasesAcute Graft Versus Host Disease, Malignant Hematologic Neoplasm · Anhui Provincial Hospital | Phase 2 | Not yet recruiting | Jun 28, 2024 |
| 1 vs 7 RATG Infusions in Renal TransplantationKidney Replacement · Mario Negri Institute for Pharmacological Research | — | Active, not recruiting | Apr 18, 2024 |
| Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDiesRenal Transplant Rejection, Induction Therapy · University Hospital, Tours | Phase 3 | Recruiting | May 23, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis